Lipocine Inc (LPCN)

$2.24 +0.07 (3.23%)
Market Cap 17.89M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 27,500
Avg Vol 43,552
Day's Range N/A - N/A
Shares Out 8.24M
Stochastic %K 76%
Beta 0.46
Analysts Hold
Price Target $6.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the ma...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
ultistock
ultistock Aug. 28 at 6:25 PM
$LPCN I have feeling we will hear something next week, usually pre-market Tuesday or Thursday. Unless it is bad news, then they might hit us with Friday again...
1 · Reply
agarfield
agarfield Aug. 27 at 7:25 PM
$LPCN a smaller confirmation study is my bet on the FDA meeting, which should fall within existing cash holdings. Will probably need to run some sort of dilution irregardless, but would be a recoverable option. A smaller slam dunk than what sould have been a big one. 1/3 of the patients came from the anomalous site and there was a sudden influx of patients from that clinic. Despite it being double-blinded, I'm surprised the company in charge did not flag that. This is why you always spend an extra dime to hire more reputable firms to run your trials. Will get back in depending on FDA readout, GL to all here.
1 · Reply
DrunkStockTrader69
DrunkStockTrader69 Aug. 27 at 4:00 PM
$LPCN I’ve been bag holding since 2019 down 20k in this stock I’m not giving up until the pipeline is officially dry.
0 · Reply
amazingcrwns
amazingcrwns Aug. 27 at 3:06 PM
$LPCN Seems like someone is interested in having a position before we find out what the FDA guidance is. It's always nice to see the share price climb up a little bit, and not surprising that there is some interest with important news approaching. Fingers crossed we get a positive update on the 1154 program sometime in the coming weeks.
0 · Reply
ultistock
ultistock Aug. 26 at 3:56 PM
$LPCN This is nothing, right?
3 · Reply
AtariLynx
AtariLynx Aug. 25 at 7:45 PM
$LPCN
0 · Reply
BioAB
BioAB Aug. 24 at 4:46 PM
$LPCN this is why we need this brilizio in market https://www.nbcboston.com/news/local/lindsay-clancy-trial-day-19-live-updates/4002724/
1 · Reply
Invescent
Invescent Aug. 19 at 7:50 PM
$LPCN April 2: Phase 3 miss: CEO buys $50.5K April 6: CEO buys another $50.75K + director buys $252K April 7: Director buys another $81K That's $434,600 in open-market insider buying after a 78% crash. Catalysts: • Fast Track + Breakthrough Therapy requests for LPCN 1154 already submitted to FDA • Awaiting FDA feedback • Validation study protocol/path forward • Potential partnership for LPCN 1154
1 · Reply
brunoq14
brunoq14 Aug. 18 at 1:16 PM
$LPCN We know that they will be submitting protocols to the FDA for POC studies in MDD and essential tremor. Maybe when we hear about one of those, we will also get additional information about the BRZILIO guidance meeting, which we know is scheduled for Q3.
2 · Reply
ultistock
ultistock Aug. 17 at 4:36 PM
$LPCN Hoping for some good news this week. I am out of funds so I cannot load up anymore. Someday hoping to break even...
2 · Reply
Latest News on LPCN
Lipocine reports Q2 EPS (32c) vs. (41c) last year

2026-08-04T12:05:40.000Z - 4 weeks ago

Lipocine reports Q2 EPS (32c) vs. (41c) last year

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Aug 4, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Quarterly report: Q2 2026

Aug 4, 2026, 7:00 AM EDT - 4 weeks ago

Lipocine Quarterly report: Q2 2026

Lipocine Earnings release: Q2 2026

Aug 4, 2026, 7:00 AM EDT - 4 weeks ago

Lipocine Earnings release: Q2 2026

Lipocine Appoints Michael J. Grissinger to Board of Directors

Aug 3, 2026, 8:00 AM EDT - 4 weeks ago

Lipocine Appoints Michael J. Grissinger to Board of Directors

Lipocine Transcript: KOL event

Jun 12, 2026, 11:00 AM EDT - 2 months ago

Lipocine Transcript: KOL event

Lipocine Slides: KOL event

Jun 12, 2026, 11:00 AM EDT - 2 months ago

Lipocine Slides: KOL event

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 3:00 PM EDT - 3 months ago

Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

May 19, 2026, 8:00 AM EDT - 3 months ago

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

May 19, 2026, 4:00 AM EDT - 3 months ago

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

May 18, 2026, 8:00 AM EDT - 3 months ago

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

May 7, 2026, 4:05 PM EDT - 4 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Lipocine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Lipocine Quarterly report: Q1 2026

Lipocine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Lipocine Earnings release: Q1 2026

Lipocine Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Lipocine Slides: Corporate presentation

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Lipocine Proxy statement: Proxy filing

Lipocine Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Lipocine Proxy statement: Proxy filing

Lipocine price target lowered to $6 from $11 at Alliance Global

2026-04-13T18:12:07.000Z - 5 months ago

Lipocine price target lowered to $6 from $11 at Alliance Global

Lipocine Slides: Investor presentation

Apr 13, 2026, 7:00 AM EDT - 5 months ago

Lipocine Slides: Investor presentation

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Apr 6, 2026, 7:56 AM EDT - 5 months ago

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

2026-04-06T10:16:57.000Z - 5 months ago

Lipocine downgraded to Neutral from Buy at H.C. Wainwright

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

2026-04-02T12:07:46.000Z - 5 months ago

Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 5 months ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $11 from $6.75 at Alliance Global

2026-03-17T16:00:59.000Z - 6 months ago

Lipocine price target raised to $11 from $6.75 at Alliance Global

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Earnings release: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 6 months ago

Lipocine Earnings release: Q4 2025

Lipocine Annual report: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 6 months ago

Lipocine Annual report: Q4 2025

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

2026-02-18T13:05:35.000Z - 6 months ago

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Feb 18, 2026, 8:00 AM EST - 6 months ago

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 6 months ago

Lipocine Slides: Corporate presentation

Lipocine price target raised to $15 from $7 at H.C. Wainwright

2026-01-21T11:15:46.000Z - 7 months ago

Lipocine price target raised to $15 from $7 at H.C. Wainwright

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

2026-01-20T13:05:41.000Z - 8 months ago

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 8 months ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

2026-01-12T13:16:24.000Z - 8 months ago

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 8 months ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

2025-12-16T13:06:09.000Z - 9 months ago

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 9 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

2025-11-18T14:44:20.000Z - 10 months ago

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 10 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

2025-11-13T11:20:38.000Z - 10 months ago

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

Lipocine reports Q3 EPS (59c) vs. (44c) last year

2025-11-06T13:06:28.000Z - 10 months ago

Lipocine reports Q3 EPS (59c) vs. (44c) last year

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Lipocine Earnings release: Q3 2025

Lipocine Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Lipocine Quarterly report: Q3 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 10 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine provides update on Phase 3 clinical trial in postpartum depression

2025-09-30T12:10:40.000Z - 1 year ago

Lipocine provides update on Phase 3 clinical trial in postpartum depression

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 1 year ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine reports Q2 EPS (41c) vs. (57c) last year

2025-08-05T12:05:16.000Z - 1 year ago

Lipocine reports Q2 EPS (41c) vs. (57c) last year

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Quarterly report: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

Lipocine Quarterly report: Q2 2025

Lipocine Earnings release: Q2 2025

Aug 5, 2025, 6:00 AM EDT - 1 year ago

Lipocine Earnings release: Q2 2025

Lipocine Transcript: Status Update

Jul 9, 2025, 11:00 AM EDT - 1 year ago

Lipocine Transcript: Status Update

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

2025-06-26T12:05:39.000Z - 1 year ago

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine announces filing of NDA for TLANDO in Canada

2025-06-09T12:10:36.000Z - 1 year ago

Lipocine announces filing of NDA for TLANDO in Canada

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine assumed with a Buy at H.C. Wainwright

2025-05-29T14:45:19.000Z - 1 year ago

Lipocine assumed with a Buy at H.C. Wainwright

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 4:00 PM EDT - 1 year ago

Lipocine Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Earnings release: Q1 2025

Lipocine Quarterly report: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Lipocine Quarterly report: Q1 2025

Lipocine announces license and supply agreement with Ache

2025-05-06T12:17:57.000Z - 1 year ago

Lipocine announces license and supply agreement with Ache

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Lipocine Proxy statement: Proxy Filing

Lipocine initiates Phase 3 trial for LPCN 1154

2025-03-26T12:06:51.000Z - 1 year ago

Lipocine initiates Phase 3 trial for LPCN 1154

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Earnings release: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Earnings release: Q4 2024

Lipocine Annual report: Q4 2024

Mar 13, 2025, 11:30 AM EDT - 1 year ago

Lipocine Annual report: Q4 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Press release: Corporate Presentation

Dec 12, 2024, 7:00 PM EST - 1 year ago

Lipocine Press release: Corporate Presentation

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Quarterly report: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Quarterly report: Q3 2024

Lipocine Earnings release: Q3 2024

Nov 6, 2024, 6:00 PM EST - 1 year ago

Lipocine Earnings release: Q3 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Transcript: Status Update

Oct 15, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Status Update

Lipocine Slides: Status Update

Oct 15, 2024, 6:00 PM EDT - 2 years ago

Lipocine Slides: Status Update

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 2 years ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 2 years ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

Lipocine Quarterly report: Q2 2024

Lipocine Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

Lipocine Earnings release: Q2 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Quarterly report: Q1 2024

Lipocine Earnings release: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Lipocine Earnings release: Q1 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Registration statement: Registration Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Registration statement: Registration Filing

Lipocine Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Lipocine Proxy statement: Proxy Filing

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Transcript: Study Result

Apr 10, 2024, 6:00 PM EDT - 2 years ago

Lipocine Transcript: Study Result

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

ultistock
ultistock Aug. 28 at 6:25 PM
$LPCN I have feeling we will hear something next week, usually pre-market Tuesday or Thursday. Unless it is bad news, then they might hit us with Friday again...
1 · Reply
agarfield
agarfield Aug. 27 at 7:25 PM
$LPCN a smaller confirmation study is my bet on the FDA meeting, which should fall within existing cash holdings. Will probably need to run some sort of dilution irregardless, but would be a recoverable option. A smaller slam dunk than what sould have been a big one. 1/3 of the patients came from the anomalous site and there was a sudden influx of patients from that clinic. Despite it being double-blinded, I'm surprised the company in charge did not flag that. This is why you always spend an extra dime to hire more reputable firms to run your trials. Will get back in depending on FDA readout, GL to all here.
1 · Reply
DrunkStockTrader69
DrunkStockTrader69 Aug. 27 at 4:00 PM
$LPCN I’ve been bag holding since 2019 down 20k in this stock I’m not giving up until the pipeline is officially dry.
0 · Reply
amazingcrwns
amazingcrwns Aug. 27 at 3:06 PM
$LPCN Seems like someone is interested in having a position before we find out what the FDA guidance is. It's always nice to see the share price climb up a little bit, and not surprising that there is some interest with important news approaching. Fingers crossed we get a positive update on the 1154 program sometime in the coming weeks.
0 · Reply
ultistock
ultistock Aug. 26 at 3:56 PM
$LPCN This is nothing, right?
3 · Reply
AtariLynx
AtariLynx Aug. 25 at 7:45 PM
$LPCN
0 · Reply
BioAB
BioAB Aug. 24 at 4:46 PM
$LPCN this is why we need this brilizio in market https://www.nbcboston.com/news/local/lindsay-clancy-trial-day-19-live-updates/4002724/
1 · Reply
Invescent
Invescent Aug. 19 at 7:50 PM
$LPCN April 2: Phase 3 miss: CEO buys $50.5K April 6: CEO buys another $50.75K + director buys $252K April 7: Director buys another $81K That's $434,600 in open-market insider buying after a 78% crash. Catalysts: • Fast Track + Breakthrough Therapy requests for LPCN 1154 already submitted to FDA • Awaiting FDA feedback • Validation study protocol/path forward • Potential partnership for LPCN 1154
1 · Reply
brunoq14
brunoq14 Aug. 18 at 1:16 PM
$LPCN We know that they will be submitting protocols to the FDA for POC studies in MDD and essential tremor. Maybe when we hear about one of those, we will also get additional information about the BRZILIO guidance meeting, which we know is scheduled for Q3.
2 · Reply
ultistock
ultistock Aug. 17 at 4:36 PM
$LPCN Hoping for some good news this week. I am out of funds so I cannot load up anymore. Someday hoping to break even...
2 · Reply
AtariLynx
AtariLynx Aug. 14 at 10:21 PM
$LPCN 810.000 shares… they must know something that we don’t know.
2 · Reply
amazingcrwns
amazingcrwns Aug. 14 at 9:09 PM
$LPCN Wow, I'm pleasantly surprised to see Squadron is still invested. I thought they would have been the ones dumping shares on the failed topline.
0 · Reply
AtariLynx
AtariLynx Aug. 13 at 7:00 PM
$LPCN Come on!
0 · Reply
BioAB
BioAB Aug. 13 at 12:15 AM
$LPCN
0 · Reply
brunoq14
brunoq14 Aug. 12 at 9:24 PM
$LPCN Added some more shares today and lowered my basis to 2.36. Maybe a few more if we dip below $2.
1 · Reply
ultistock
ultistock Aug. 11 at 12:52 AM
$LPCN Any word on the Tlando Canada approval? And the once a day pill? Just looking for a distraction while I await the FDA update.
1 · Reply
amazingcrwns
amazingcrwns Aug. 10 at 2:28 PM
$LPCN Added to my position. I like the addition to the board, I like that the earnings report has the comparison between the failed topline and the epidemiologic outlier site rather than a comparison with the psychiatric history subgroup and I like the trial has been initiated. I don't know if the FDA will agree with the company analysis, but I'm optimistic enough to add a little to my position with the intent of flipping these shares on the FDA guidance. It's always risky betting on the FDA so fingers crossed.
1 · Reply
amazingcrwns
amazingcrwns Aug. 4 at 12:05 PM
$LPCN "We have requested a guidance meeting with the FDA and the meeting is scheduled for the third quarter of 2026. We have initiated a new placebo controlled clinical trial for PPD to complement the existing LPCN 1154 clinical database, and to further characterize the efficacy and safety of LPCN 1154." Interesting that they have initiated a new study before the guidance meeting. I hope they already have some informal feedback indicating that will be the path forward. Assuming thats the case, its nice to see them getting the ball rolling so quickly.
2 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 4 at 10:13 AM
$LPCN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.32 up 21.95% YoY • Reported revenue of $0.19M down -69.48% YoY
0 · Reply
BioAB
BioAB Aug. 3 at 5:41 PM
$LPCN awaiting yall. Hopefully by December will be entering more. Currently just in MU and doing some trades.
1 · Reply
AtariLynx
AtariLynx Aug. 3 at 3:22 PM
$LPCN price is low, at least it should be near or over $ 3.
1 · Reply
amazingcrwns
amazingcrwns Aug. 3 at 12:52 PM
$LPCN https://ir.lipocine.com/2026-08-03-Lipocine-Appoints-Michael-J-Grissinger-to-Board-of-Directors
0 · Reply